Akèy › Limfòm selil B › Tennessee › Nashville
Etid klinik pou Limfòm selil B nan Nashville, TN
11 etid pou Limfòm selil B ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
- Tennessee Oncology Nashville St Thomas Midtown Clinic, Nashville
- Tennessee Oncology, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- Research Site, Franklin · 17 mi lwen
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 3
- Sarah Cannon Research Institute SCRI, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
Etid Limfòm selil B nan lòt vil
- New York City, NY18 etid
- Houston, TX16 etid
- Chicago, IL13 etid
- Philadelphia, PA11 etid
- Rochester, MN10 etid
- Milwaukee, WI9 etid
- Baldwin Park, CA9 etid
- Cleveland, OH9 etid
- Boston, MA8 etid
- Salt Lake City, UT8 etid
- Washington, DC7 etid
- Charlotte, NC7 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.